Acorda Therapeutics, Inc. (ACOR)

$12.2659

-0.25

(-2.03%)▲

Market is closed - opens 8 PM, 11 Dec 2023

Insights on Acorda Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 29.67M → 27.71M (in $), with an average decrease of 6.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -16.82M → -8.88M (in $), with an average increase of 42.4% per quarter

  • Vs ZTS

    In the last 1 year, Zoetis Inc. has given 20.3% return, outperforming this stock by 13.7%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 15.7% return, outperforming this stock by 102.1%

Performance

  • $12.01
    $13.40
    $12.27
    downward going graph

    2.12%

    Downside

    Day's Volatility :10.37%

    Upside

    8.43%

    downward going graph
  • $0.45
    $18.20
    $12.27
    downward going graph

    96.34%

    Downside

    52 Weeks Volatility :97.53%

    Upside

    32.58%

    downward going graph

Returns

PeriodAcorda Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-8.41%
-0.7%
0.0%
6 Months
21.69%
1.3%
0.0%
1 Year
9.52%
-4.3%
-1.5%
3 Years
-86.37%
18.3%
-7.5%

Highlights

Market Capitalization
12.9M
Book Value
$47.47
Dividend Share
0.0
Dividend Yield
1.86%
Earnings Per Share (EPS)
2.61
PE Ratio
3.98
PEG Ratio
0.51
Wall Street Target Price
10.0
Profit Margin
-14.36%
Operating Margin TTM
-27.86%
Return On Assets TTM
-3.32%
Return On Equity TTM
-23.68%
Revenue TTM
111.1M
Revenue Per Share TTM
87.94
Quarterly Revenue Growth YOY
-17.299999999999997%
Gross Profit TTM
82.4M
EBITDA
11.5M
Diluted Eps TTM
2.61
Quarterly Earnings Growth YOY
5.87
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    100%Buy
    0
    0%Hold
    0
    0%Sell
Based on 1 Wall street analysts offering stock ratings for Acorda Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 1 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
6
6
Hold
00
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 18.47%

Current $12.27
Target $10.00

Company Financials

FY17Y/Y Change
Revenue
588.3M
↑ 13.22%
Net Income
-223.4M
↑ 545.21%
Net Profit Margin
-37.97%
↓ 31.31%
FY18Y/Y Change
Revenue
471.4M
↓ 19.86%
Net Income
33.7M
↓ 115.08%
Net Profit Margin
7.14%
↑ 45.11%
FY19Y/Y Change
Revenue
192.4M
↓ 59.19%
Net Income
-273.0M
↓ 910.42%
Net Profit Margin
-141.87%
↓ 149.01%
FY20Y/Y Change
Revenue
153.0M
↓ 20.5%
Net Income
-99.6M
↓ 63.51%
Net Profit Margin
-65.11%
↑ 76.76%
FY21Y/Y Change
Revenue
129.1M
↓ 15.62%
Net Income
-104.0M
↑ 4.38%
Net Profit Margin
-80.54%
↓ 15.43%
FY22Y/Y Change
Revenue
118.6M
↓ 8.14%
Net Income
-65.9M
↓ 36.59%
Net Profit Margin
-55.59%
↑ 24.95%
Q2 FY22Q/Q Change
Revenue
31.1M
↑ 37.8%
Net Income
-46.7M
↑ 90.37%
Net Profit Margin
-150.34%
↓ 41.52%
Q3 FY22Q/Q Change
Revenue
33.5M
↑ 7.92%
Net Income
-13.9M
↓ 70.32%
Net Profit Margin
-41.34%
↑ 109.0%
Q4 FY22Q/Q Change
Revenue
31.5M
↓ 6.08%
Net Income
19.1M
↓ 238.18%
Net Profit Margin
60.83%
↑ 102.17%
Q1 FY23Q/Q Change
Revenue
22.3M
↓ 29.28%
Net Income
-16.8M
↓ 187.88%
Net Profit Margin
-75.59%
↓ 136.42%
Q2 FY23Q/Q Change
Revenue
29.7M
↑ 33.32%
Net Income
-9.4M
↓ 44.24%
Net Profit Margin
-31.61%
↑ 43.98%
Q3 FY23Q/Q Change
Revenue
27.7M
↓ 6.6%
Net Income
-8.9M
↓ 5.26%
Net Profit Margin
-32.07%
↓ 0.46%
FY17Y/Y Change
Total Assets
1.2B
↓ 10.75%
Total Liabilities
678.0M
↓ 0.02%
FY18Y/Y Change
Total Assets
1.3B
↑ 8.49%
Total Liabilities
687.7M
↑ 1.43%
FY19Y/Y Change
Total Assets
799.7M
↓ 38.47%
Total Liabilities
488.9M
↓ 28.91%
FY20Y/Y Change
Total Assets
632.7M
↓ 20.89%
Total Liabilities
394.7M
↓ 19.26%
FY21Y/Y Change
Total Assets
455.5M
↓ 28.01%
Total Liabilities
304.3M
↓ 22.9%
FY22Y/Y Change
Total Assets
395.6M
↓ 13.15%
Total Liabilities
302.0M
↓ 0.78%
Q2 FY22Q/Q Change
Total Assets
406.3M
↓ 4.2%
Total Liabilities
318.4M
↑ 7.36%
Q3 FY22Q/Q Change
Total Assets
393.3M
↓ 3.19%
Total Liabilities
317.6M
↓ 0.26%
Q4 FY22Q/Q Change
Total Assets
395.6M
↑ 0.57%
Total Liabilities
302.0M
↓ 4.91%
Q1 FY23Q/Q Change
Total Assets
374.9M
↓ 5.23%
Total Liabilities
297.9M
↓ 1.33%
Q2 FY23Q/Q Change
Total Assets
364.7M
↓ 2.72%
Total Liabilities
296.8M
↓ 0.38%
Q3 FY23Q/Q Change
Total Assets
366.3M
↑ 0.45%
Total Liabilities
307.4M
↑ 3.56%
FY17Y/Y Change
Operating Cash Flow
96.5M
↑ 173.01%
Investing Cash Flow
-10.7M
↓ 85.48%
Financing Cash Flow
61.5M
↑ 33.94%
FY18Y/Y Change
Operating Cash Flow
150.8M
↑ 56.26%
Investing Cash Flow
-176.9M
↑ 1550.94%
Financing Cash Flow
12.8M
↓ 79.2%
FY19Y/Y Change
Operating Cash Flow
-128.2M
↓ 185.0%
Investing Cash Flow
-505.0K
↓ 99.71%
Financing Cash Flow
-60.6M
↓ 573.16%
FY20Y/Y Change
Operating Cash Flow
-61.0M
↓ 52.4%
Investing Cash Flow
59.4M
↓ 11854.46%
Financing Cash Flow
-1.7M
↓ 97.25%
FY21Y/Y Change
Operating Cash Flow
-41.3M
↓ 32.22%
Investing Cash Flow
73.8M
↑ 24.29%
Financing Cash Flow
-69.7M
↑ 4075.96%
FY22Y/Y Change
Operating Cash Flow
-20.9M
↓ 49.4%
Investing Cash Flow
-136.0K
↓ 100.18%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY22Q/Q Change
Operating Cash Flow
-14.5M
↑ 6.43%
Investing Cash Flow
-70.0K
↑ 79.49%
Financing Cash Flow
0.0
-
Q3 FY22Q/Q Change
Operating Cash Flow
-1.8M
↓ 87.33%
Investing Cash Flow
-150.0K
↑ 114.29%
Financing Cash Flow
-1000.0
-
Q4 FY22Q/Q Change
Operating Cash Flow
9.1M
↓ 592.99%
Investing Cash Flow
123.0K
↓ 182.0%
Financing Cash Flow
1000.0
↓ 200.0%

Technicals Summary

Sell

Neutral

Buy

Acorda Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc.
28.17%
21.69%
9.52%
-86.37%
-99.37%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
6.38%
25.45%
-1.84%
30.01%
36.75%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.25%
0.74%
5.27%
10.53%
10.53%
Zoetis Inc.
Zoetis Inc.
9.34%
11.51%
20.76%
15.71%
105.57%
Viatris Inc.
Viatris Inc.
9.83%
4.57%
-11.76%
-43.31%
-39.84%
Catalent, Inc.
Catalent, Inc.
12.33%
-13.09%
-18.29%
-60.96%
2.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc.
3.98
3.98
0.51
0.0
-0.24
-0.03
0.02
47.47
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
61.64
61.64
1.87
2.29
0.11
0.09
0.01
20.39
Haleon Plc Spon Ads
Haleon Plc Spon Ads
25.24
25.24
3.06
0.41
0.06
0.04
0.01
1.78
Zoetis Inc.
Zoetis Inc.
36.48
36.48
2.99
5.42
0.47
0.14
0.01
11.05
Viatris Inc.
Viatris Inc.
6.19
6.19
NA
2.95
0.09
0.03
0.05
17.39
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.63
1.01
-0.22
0.0
0.0
21.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc.
Buy
$12.9M
-99.37%
3.98
-14.36%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.5B
36.75%
61.64
10.71%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$39.6B
10.53%
25.24
11.05%
Zoetis Inc.
Zoetis Inc.
Buy
$82.2B
105.57%
36.48
27.24%
Viatris Inc.
Viatris Inc.
Hold
$11.2B
-39.84%
6.19
11.84%
Catalent, Inc.
Catalent, Inc.
Hold
$7.2B
2.51%
211.02
-22.36%

Institutional Holdings

  • Davidson Kempner Capital Management LP

    4.44%

  • Renaissance Technologies Corp

    3.71%

  • Acadian Asset Management LLC

    2.71%

  • Vanguard Group Inc

    0.86%

  • BlackRock Inc

    0.55%

  • Wells Fargo & Co

    0.30%

Company Information

acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate

Organization
Acorda Therapeutics, Inc.
Employees
111
CEO
Dr. Ron Cohen M.D.
Industry
Health Technology

Discover More

FAQs